Biocon Share Price in Focus; Net Profit Surges 323% in FY26 Results

Biocon Limited announced its consolidated financial results for the quarter and financial year ended March 31, 2026, reporting strong growth across key financial metrics.

For Q4FY26, the company posted total income of ₹4,569 crore, up 10% year-on-year after adjusting for one-time generic lenalidomide sales in the previous year. Operating revenue stood at ₹4,517 crore, while EBITDA rose 29% YoY to ₹1,073 crore. EBITDA margin improved to 23%.

Net profit before exceptional items came in at ₹179 crore, registering a 64% increase compared to the corresponding quarter last year.

FY26 Financial Highlights

For the full financial year FY26, Biocon reported total income of ₹17,270 crore, marking a 14% rise. Operating revenue stood at ₹16,927 crore, up 13% YoY.

EBITDA for FY26 increased 25% to ₹3,798 crore, while EBITDA margin improved by 200 basis points to 22% on a like-to-like basis. Net profit before exceptional items surged 323% to ₹436 crore.

The company also continued investing in research and development, with net R&D investment reaching ₹982 crore during FY26.

Biosimilars Segment Drives Growth

The Biosimilars business remained the key growth driver for the company. Q4FY26 revenue from the segment rose 12% YoY to ₹2,756 crore, while FY26 revenue increased 16% to ₹10,431 crore.

The Generics segment also showed steady growth, while Syngene’s research services business contributed ₹3,739 crore in FY26 revenue.

Dividend and Management Updates

The Board of Directors recommended a final dividend of Re 0.50 per share, representing 10% of the face value for FY26.

The company also announced leadership and board changes. Shreehas Tambe assumed charge as CEO and Managing Director from April 1, 2026, while Kedar Upadhye was appointed CFO.

Biocon Share Price Today

On May 8, 2026, Biocon share price opened at ₹379.00, touching the day’s high at ₹396.40, as of 11:31 AM on the NSE.

Also Read: Biocon Scales Biosimilars And Prepares Global Semaglutide Expansion!

Conclusion

Biocon’s FY26 performance reflects strong operational execution and growth across core business segments, particularly biosimilars. Improved profitability, expanding revenues, and continued investment in innovation position the company for long-term growth in the global biopharmaceutical market.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a private recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.